Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
We all get tired after a long day, a demanding week, or a late night
Finally, opt for a supplement from a reputable manufacturer to be sure of safety and quality, like Performance Lab Immune
Some days I was probably getting 40 grams total, which is nowhere near enough
Studies involving rats demonstrated that MT-2 reduced alcohol consumption while increasing water intake, indicating its potential influence on impulse control and beverage preference
One concern that sometimes comes up is whether Wegovy could increase the risk of vaginal yeast infections
